Sign In
Buy RMD
$188.63
+2.34 (+1.26%)
At Close: Jun 18, 2026
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
09:46am, Wednesday, 25'th Feb 2026
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RL, EAT, FTI and RMD hold promise.
Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana
09:00am, Tuesday, 24'th Feb 2026
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distributi
Dana Investment Advisors Inc. Sells 4,272 Shares of ResMed Inc. $RMD
04:52am, Tuesday, 24'th Feb 2026
Dana Investment Advisors Inc. reduced its stake in ResMed Inc. (NYSE: RMD) by 13.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchang
Apriem Advisors Lowers Holdings in ResMed Inc. $RMD
03:06am, Tuesday, 24'th Feb 2026
Apriem Advisors reduced its stake in shares of ResMed Inc. (NYSE: RMD) by 8.5% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Com
Aberdeen Group plc Has $75.94 Million Stake in ResMed Inc. $RMD
03:16am, Monday, 16'th Feb 2026
Aberdeen Group plc decreased its holdings in shares of ResMed Inc. (NYSE: RMD) by 6.6% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange
ResMed Inc. (NYSE:RMD) Receives Average Recommendation of “Moderate Buy” from Brokerages
01:52am, Friday, 13'th Feb 2026
Shares of ResMed Inc. (NYSE: RMD - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are currently covering the company, Marketbeat reports.
Market Today: Tech Sells Off on AI Jitters; M&A, FDA Moves and Policy Shifts
05:35pm, Thursday, 12'th Feb 2026
Guru Stock PicksAl Gore has made the following transactions:Reduce in NTNX by 46.77%Sold out in MCHPAdd in MELI by 2.52%New position in CSLKen Fisher has made t
First Look: McDonald's beats, Hims sued, WBD deal battle
07:39am, Thursday, 12'th Feb 2026
Stock News Futures edge up as jobs data and earnings mix: U.S. stock futures inched higher after January payrolls rose 130,000 with unemployment at 4.3%, compli
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
12:35pm, Monday, 09'th Feb 2026
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. APH, GE, RMD and AMP are some such stocks.
RMD Stock Up Following Q2 Earnings & Revenue Beat, Margins Expand
09:05am, Friday, 06'th Feb 2026
Resmed shares rise after Q2 EPS and revenues beat expectations, with the gross and operating margins expanding sharply across core segments.
4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
06:41am, Tuesday, 03'rd Feb 2026
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge
12:29am, Tuesday, 03'rd Feb 2026
Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1
4 Medical Product Stocks to Watch From a Challenging Industry
10:11am, Monday, 02'nd Feb 2026
The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell
12:54am, Sunday, 01'st Feb 2026
ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell
Analysts Maintain Bull Case On ResMed Despite Competition Concerns
01:08pm, Friday, 30'th Jan 2026
On Thursday, ResMed Inc (NYSE: RMD) reported that second-quarter fiscal 2026 adjusted earnings of 2.81, beating the consensus of $2.72.
